A Cutting-Edge Cancer Treatment Is Under FDA Investigation—for Cancer Risk
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers. Read this story here. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Science, Spoken · SpokenLayer
November 30, 20236m 58s
Audio is streamed directly from the publisher (dovetail.prxu.org) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers.
Read this story here.
Learn about your ad choices: dovetail.prx.org/ad-choices